| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/12/2006 | CA2648522A1 Substituted azetidinones |
| 10/12/2006 | CA2614526A1 Benzimidazole formulation |
| 10/12/2006 | CA2605386A1 Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| 10/12/2006 | CA2604861A1 Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor |
| 10/12/2006 | CA2604396A1 Therapeutic use of nefopam and analogues thereof |
| 10/12/2006 | CA2604161A1 Purine and imidazopyridine derivatives for immunosuppression |
| 10/12/2006 | CA2604133A1 Compounds useful as modulators of the proteasome activity |
| 10/12/2006 | CA2604021A1 Piperidyl-2, 6-dione derivatives used to inhibit cells from releasing tumor necrosis factor |
| 10/12/2006 | CA2604016A1 Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives |
| 10/12/2006 | CA2603943A1 An oxindole oxazolidinone as antibacterial agent |
| 10/12/2006 | CA2603939A1 Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors |
| 10/12/2006 | CA2603926A1 Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain |
| 10/12/2006 | CA2603899A1 7-fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents |
| 10/12/2006 | CA2603826A1 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
| 10/12/2006 | CA2603748A1 C-met modulators and methods of use |
| 10/12/2006 | CA2603688A1 Methods of protection from oxidative stress |
| 10/12/2006 | CA2603512A1 Anti-inflammatory formulation |
| 10/12/2006 | CA2603509A1 Crystal form of asenapine maleate |
| 10/12/2006 | CA2603493A1 Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and their use in the production of medicaments |
| 10/12/2006 | CA2603478A1 Indazole squaric acid derivatives as chk1-, chk2- and sgk- inhibitors |
| 10/12/2006 | CA2603475A1 Acyl hydrazides as kinase inhibitors, in particular for sgk |
| 10/12/2006 | CA2603472A1 Pyrazole derivatives |
| 10/12/2006 | CA2603403A1 Skin enrichment using coq10 as the delivery system |
| 10/12/2006 | CA2603398A1 Sulfonylpyrroles as histone deacetylase inhibitors |
| 10/12/2006 | CA2603385A1 Desferrithiocin polyether analogues and uses thereof for treating metal overload, oxidative stress, and neoplastic and preneoplastic conditions |
| 10/12/2006 | CA2603347A1 Oil-in-water emulsions of lignans that exhibit improved absorption rate |
| 10/12/2006 | CA2603304A1 Substituted benzylimidazoles useful for the treatment of inflammatory diseases |
| 10/12/2006 | CA2603258A1 Dihydropyridine compounds and compositions for headaches |
| 10/12/2006 | CA2603250A1 Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors |
| 10/12/2006 | CA2603245A1 Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
| 10/12/2006 | CA2603214A1 Derivatives of[6,7-dihydro-5himidazo[1,2-alpha]imidazole-3-sulfonyl]-azetedine-carboxylic acids, esters and amides and use thereof as anti-inflammatory agents |
| 10/12/2006 | CA2603129A1 Crystalline forms of pregabalin |
| 10/12/2006 | CA2603127A1 Use of spirostenols to treat mitochondrial disorders |
| 10/12/2006 | CA2603104A1 Tetrahydrothiopyrano pyrazole cannabinoid modulators |
| 10/12/2006 | CA2603081A1 Device and methods for treating paranasal sinus conditions |
| 10/12/2006 | CA2603063A1 Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods |
| 10/12/2006 | CA2603030A1 Benzyloxypropylamine derivative |
| 10/12/2006 | CA2602800A1 Pyrazolopyridines and analogs thereof |
| 10/12/2006 | CA2602796A1 Oils of capsaicinoids and methods of making and using the same |
| 10/12/2006 | CA2602794A1 Stannsoporfin compositions and administration |
| 10/12/2006 | CA2602787A1 Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
| 10/12/2006 | CA2602757A1 Substituted 1,5-naphthyridine azolidinones as cdk inhibitors |
| 10/12/2006 | CA2602683A1 Pyrazolopyridine-1,4-diamines and analogs thereof |
| 10/12/2006 | CA2602624A1 Benzimidazole derivative and use as angiotensin ii antagonist |
| 10/12/2006 | CA2602623A1 Substituted 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs |
| 10/12/2006 | CA2602590A1 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| 10/12/2006 | CA2602532A1 Pyrrolo [2,3-d] imidazoles for the treatment of hyperproliferative disorders |
| 10/12/2006 | CA2602467A1 Bcrp/abcg2 inhibitor |
| 10/12/2006 | CA2602372A1 Pyrimidine derivatives for use as anticancer agents |
| 10/12/2006 | CA2602234A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 10/12/2006 | CA2602231A1 Prevention of hiv-infection |
| 10/12/2006 | CA2602228A1 Triamine derivative |
| 10/12/2006 | CA2602025A1 Tricyclic spiro compound comprising acyl group bound to nitrogen atom in the ring |
| 10/12/2006 | CA2601988A1 Prophylactic or therapeutic agent for noctural conduct disorder associated with dementia |
| 10/12/2006 | CA2601983A1 Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| 10/12/2006 | CA2601705A1 Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference |
| 10/12/2006 | CA2601649A1 Process for the preparation of anastrozole |
| 10/12/2006 | CA2601427A1 A method and composition for nutritionally improving glucose control and insulin action |
| 10/12/2006 | CA2601374A1 Improved formulations of fenofibrate containing menthol or a peg/poloxamer mixture |
| 10/12/2006 | CA2601372A1 Improved formulations of fenofibrate containing menthol or peg/poloxamer |
| 10/12/2006 | CA2600609A1 Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
| 10/12/2006 | CA2600407A1 Fibrate compositions containing a surfactant mixture of peg-600 and poloxamer 407 |
| 10/12/2006 | CA2599922A1 Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents |
| 10/11/2006 | EP1710582A2 Suppressor genes |
| 10/11/2006 | EP1710307A2 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 10/11/2006 | EP1710257A1 Hyaluronic acid derivative and drug containing the same |
| 10/11/2006 | EP1710254A2 Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 10/11/2006 | EP1710249A1 Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound |
| 10/11/2006 | EP1710248A1 Novel aminoglycoside antibiotic effective against methicillin resistant staphylococcus aureus (mrsa) |
| 10/11/2006 | EP1710246A1 Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| 10/11/2006 | EP1710245A1 Crystal form of asenapine maleate |
| 10/11/2006 | EP1710243A1 Therapeutic agent for vasospasm accompanying bypass operation |
| 10/11/2006 | EP1710242A1 Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha levels |
| 10/11/2006 | EP1710240A1 Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists |
| 10/11/2006 | EP1710239A1 Process for producing chroman compound |
| 10/11/2006 | EP1710238A1 Benzophenones as inhibitors of reverse transcriptase |
| 10/11/2006 | EP1710236A1 Derivatives of pyridine and quinoline |
| 10/11/2006 | EP1710235A1 Extracts of marasmins androsaceus l.es, piperdinone derivatives and the use as antihypertensive agents |
| 10/11/2006 | EP1710231A1 CETP activity inhibitors |
| 10/11/2006 | EP1709975A1 Tablet and process for producing the same |
| 10/11/2006 | EP1709974A2 Method of treating cardiovascular disease using rapamycin |
| 10/11/2006 | EP1709973A1 Method of suppressing cancer |
| 10/11/2006 | EP1709972A1 Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types |
| 10/11/2006 | EP1709968A1 P2x receptor inhibitor |
| 10/11/2006 | EP1709967A1 Agents for treating migraine |
| 10/11/2006 | EP1709966A1 Preventive and/or therapeutic agent for higher brain dysfunction |
| 10/11/2006 | EP1709965A2 Methods of treating cytokine mediate diseases |
| 10/11/2006 | EP1709964A2 A method of cosmetic depigmentation care by applying at least one aurone |
| 10/11/2006 | EP1709963A2 Use of amtolmetin guacyl for the production of a drug for counteracting blood platelet aggregation |
| 10/11/2006 | EP1709962A1 The use of l-butylphthalide in the manufacturing of medicines for the prevention and treatment of cerebral ischemia disease |
| 10/11/2006 | EP1709961A1 Use of Docosahexaenoic Acid and/or Arachidonic Acid for preventing or treating respiratory infections in infants |
| 10/11/2006 | EP1709960A2 Use of alkanoic acid-containing compositions for straightening hair |
| 10/11/2006 | EP1709959A1 Reagent for lacrimation examination and method of lacrimation examination |
| 10/11/2006 | EP1709957A2 Sustained-release analgesic compounds |
| 10/11/2006 | EP1709194A2 DELIVERY OF DNA OR RNA VIA GAP JUNCTIONS FROM HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SiRNA |
| 10/11/2006 | EP1709193A2 Methods and materials for assessing prostate cancer therapies |
| 10/11/2006 | EP1709177A2 Dna-sequence and recombinant production of group 4 major allergens from cereals |
| 10/11/2006 | EP1709176A1 Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders |
| 10/11/2006 | EP1709175A2 Hif oligonucleotide decoy molecules |
| 10/11/2006 | EP1709173A2 Methods for inducing differentiation of undifferentiated mammalian cells into osteoblasts |